Page last updated: 2024-11-13

inotodiol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

inotodiol: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID44422314
CHEMBL ID449088
SCHEMBL ID24065966
MeSH IDM0506650

Synonyms (11)

Synonym
inotodiol
CHEMBL449088
Q15634152
MS-27970
DTXSID10957379
(22r)-5alpha-lanosta-8,24-diene-3beta,22-diol
HY-120149
CS-0077023
SCHEMBL24065966
E83702
AKOS040744638

Research Excerpts

Overview

Inotodiol is a lanostane triterpenoid isolated from Inonotus obliquus. It had been extensively reported to be an anti-inflammatory agent. Its effect on arthritis remains unknown.

ExcerptReferenceRelevance
"Inotodiol is a lanostane triterpenoid that demonstrates antiviral, anticancer, and anti-inflammatory activities."( Antiaging effect of inotodiol on oxidative stress in human dermal fibroblasts.
Choi, SH; Kim, MY; Lee, SH; Oh, CH; Park, JI; Park, JT; Won, GW, 2022
)
1.77
"Inotodiol is a lanostane triterpenoid isolated from Inonotus obliquus, which had been extensively reported to be an anti-inflammatory agent, but its effect on arthritis remains unknown."( Inotodiol ameliorates the progression of osteoarthritis: An in vitro and in vivo study.
Hu, W; Ji, R; Li, X; Pan, H; Qian, W; Ye, Q; Zhou, L, 2023
)
3.07
"Inotodiol is a lanostane triterpenoid found only in Chaga mushroom. "( Anti-allergic effect of inotodiol, a lanostane triterpenoid from Chaga mushroom, via selective inhibition of mast cell function.
Hwang, I; Kim, YH; Le, BV; Le, HS; Nguyen, TMN, 2020
)
2.31
"Inotodiol is a lanostane triterpenoid found in natural resources like edible mushroom Inonotus obliquus."( Inotodiol suppresses proliferation of breast cancer in rat model of type 2 diabetes mellitus via downregulation of β-catenin signaling.
Bao, C; Zhang, J; Zhang, X, 2018
)
2.64

Effects

ExcerptReferenceRelevance
"Inotodiol has been proven to have antitumor, antiviral, anti-inflammatory, and antiallergic properties. "( Inotodiol suppresses allergic inflammation in allergic rhinitis mice.
Choi, MR; Chung, EH; Chung, J; Kang, JY; Kim, YM; Park, JT; Park, SK, 2023
)
3.8

Actions

ExcerptReferenceRelevance
"Inotodiol can inhibit proliferation and induce the apoptosis of A549 cells, and its molecular mechanism may be associated with the up-regulating expression of p53 and bax proteins and down-regulating expression of Bcl-2 protein, which arrested A549 cells in S phase."( Effects of inotodiol extracts from inonotus obliquus on proliferation cycle and apoptotic gene of human lung adenocarcinoma cell line A549.
Sun, DZ; Wang, LB; Zhong, XH, 2011
)
2.2
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID284049Cell viability in Raji cells at 1000 mol ratio/TPA relative to control2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Structure determination of inonotsuoxides A and B and in vivo anti-tumor promoting activity of inotodiol from the sclerotia of Inonotus obliquus.
AID284048Inhibition of TPA-induced EBV-EA activation in Raji cells at 10 mol ratio/TPA relative to control2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Structure determination of inonotsuoxides A and B and in vivo anti-tumor promoting activity of inotodiol from the sclerotia of Inonotus obliquus.
AID711411Cytotoxicity against human COLO205 cells2012Journal of natural products, Nov-26, Volume: 75, Issue:11
Lanostanoids from fungi: a group of potential anticancer compounds.
AID711412Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as increase in survival rate at 10 mg/kg2012Journal of natural products, Nov-26, Volume: 75, Issue:11
Lanostanoids from fungi: a group of potential anticancer compounds.
AID711414Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as increase in survival rate at 3 mg/kg2012Journal of natural products, Nov-26, Volume: 75, Issue:11
Lanostanoids from fungi: a group of potential anticancer compounds.
AID711416Cytotoxicity against human HL60 cells2012Journal of natural products, Nov-26, Volume: 75, Issue:11
Lanostanoids from fungi: a group of potential anticancer compounds.
AID284045Suppression of DMBA/TPA-induced papilloma-formation in ICR mouse within 10 week2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Structure determination of inonotsuoxides A and B and in vivo anti-tumor promoting activity of inotodiol from the sclerotia of Inonotus obliquus.
AID284044Inhibition of TPA-induced EBV-EA activation in Raji cells at 500 mol ratio/TPA relative to control2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Structure determination of inonotsuoxides A and B and in vivo anti-tumor promoting activity of inotodiol from the sclerotia of Inonotus obliquus.
AID1063365Hepatoprotective activity against D-galactosamine-induced toxicity in rat WB-F344 cells assessed as cell survival at 10 uM preincubated for 1 hr followed by D-galactosamine challenge measured after 24 hrs by MTT assay relative to normal cell2014Journal of natural products, Jan-24, Volume: 77, Issue:1
Chemical constituents from Inonotus obliquus and their biological activities.
AID284047Inhibition of TPA-induced EBV-EA activation in Raji cells at 100 mol ratio/TPA relative to control2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Structure determination of inonotsuoxides A and B and in vivo anti-tumor promoting activity of inotodiol from the sclerotia of Inonotus obliquus.
AID284050Toxicity in ICR mouse with DMBA/TPA-induced papilloma2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Structure determination of inonotsuoxides A and B and in vivo anti-tumor promoting activity of inotodiol from the sclerotia of Inonotus obliquus.
AID284043Inhibition of TPA-induced EBV-EA activation in Raji cells at 1000 mol ratio/TPA relative to control2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Structure determination of inonotsuoxides A and B and in vivo anti-tumor promoting activity of inotodiol from the sclerotia of Inonotus obliquus.
AID711410Cytotoxicity against mouse L1210 cells2012Journal of natural products, Nov-26, Volume: 75, Issue:11
Lanostanoids from fungi: a group of potential anticancer compounds.
AID1063364Hepatoprotective activity in rat WB-F344 cells assessed as inhibition of D-galactosamine-induced toxicity at 10 uM preincubated for 1 hr followed by D-galactosamine challenge measured after 24 hrs by MTT assay relative to control2014Journal of natural products, Jan-24, Volume: 77, Issue:1
Chemical constituents from Inonotus obliquus and their biological activities.
AID711413Antiproliferative activity against mouse P388 cells2012Journal of natural products, Nov-26, Volume: 75, Issue:11
Lanostanoids from fungi: a group of potential anticancer compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (9.52)29.6817
2010's10 (47.62)24.3611
2020's9 (42.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.31 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index5.38 (4.65)
Search Engine Demand Index39.34 (26.88)
Search Engine Supply Index3.00 (0.95)

This Compound (25.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.35%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (95.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]